This Article Full Text Full Text (PDF) All Versions of this Article: 38/10/2652    most recent STROKEAHA.107.487017v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Colivicchi, F. Articles by Caltagirone, C. Search for Related Content PubMed PubMed Citation Articles by Colivicchi, F. Articles by Caltagirone, C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ATORVASTATIN HEPTANOIC ACID PYRROLE Medline Plus Health Information Stroke Related Collections Compliance/Adherence Secondary prevention Related Article

(Stroke. 2007;38:2652.)
© 2007 American Heart Association, Inc.

Original Contributions

Discontinuation of Statin Therapy and Clinical Outcome After Ischemic Stroke

Furio Colivicchi, MD, FESC; Andrea Bassi, MD; Massimo Santini, MD, FESC Carlo Caltagirone, MD

From the Cardiovascular Department (F.C., M.S.), San Filippo Neri Hospital; IRCCS Santa Lucia Foundation (A.B., C.C.); and the Department of Neurology (C.C.), University of Rome "Tor Vergata," Rome, Italy.

Correspondence to Furio Colivicchi, MD, Via Gorgia da Leontini 330, 00124 Rome, Italy. E-mail furcol{at}rdn.it

Background and Purpose— The majority of patients with previous ischemic stroke are expected to benefit significantly from long-term statin therapy. However, discontinuation of medication therapy frequently occurs in clinical practice. The aim of this study was to assess the impact of discontinued statin therapy on clinical outcome in patients discharged after an acute ischemic stroke.

Methods— The study population included 631 consecutive stroke survivors (322 men and 309 women; mean±SD age, 70.2±7.6 years) without clinical evidence of coronary heart disease. All patients were discharged on statin therapy and were followed up for 12 months after the acute ischemic stroke.

Results— Within 12 months from discharge, 246 patients (38.9%) discontinued statin therapy; the mean time from discharge to statin discontinuation was 48.6±54.9 days (median time, 30 days; interquartile range, 18 to 55 days). During follow-up, 116 patients died (1-year probability of death=0.18; 95% CI, 0.15 to 0.21). Multivariate analysis demonstrated that after adjustment for all confounders and interactions, statin therapy discontinuation (hazard ratio=2.78; 95% CI, 1.96 to 3.72; P=0.003) was an independent predictor of all-cause 1-year mortality.

Conclusions— A large number of patients discontinue their use of statins early after acute stroke. Moreover, patients discontinuing statins have a significantly increased mortality during the first year after the acute cerebrovascular event. These findings suggest that patient care should be improved during the transition from a hospital setting to outpatient primary care.

Key Words: adherence • statins • stroke

Related Article:

Do We Need to Assess the Effect of Treatment Withdrawal?: The Paradigm of Life-Long Prevention

François Gueyffier and Théodora Bejan-Angoulvant
Stroke 2007 38: 2629-2630. [Full Text] [PDF]

This article has been cited by other articles:

				A. D. Auerbach Changing the Practice of Perioperative Cardioprotection: Perioperative {beta}-Blockers After POISE (PeriOperative ISchemic Evaluation) Circ Cardiovasc Qual Outcomes, September 1, 2008; 1(1): 58 - 61. [Full Text] [PDF]

				S. S. Daskalopoulou, J. A.C. Delaney, K. B. Filion, J. M. Brophy, N. E. Mayo, and S. Suissa Discontinuation of statin therapy following an acute myocardial infarction: a population-based study Eur. Heart J., September 1, 2008; 29(17): 2083 - 2091. [Abstract] [Full Text] [PDF]

				E. Ritz and C. Wanner Lipid Abnormalities and Cardiovascular Risk in Renal Disease J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1065 - 1070. [Abstract] [Full Text] [PDF]